Anzeige
Erschienen in:
27.03.2022 | Correction
Correction to: How to strengthen the management of acute diverticulitis: the utility of the WSES classification—a prospective single-center observational study
Erschienen in: European Journal of Trauma and Emergency Surgery | Ausgabe 5/2022
Einloggen, um Zugang zu erhaltenExcerpt
In this article, Table 3 unfortunately contained some mistakes in the data regarding outpatient treatment. The correct version of the Table 3 is given below:
Table 3
Clinical and analytical parameters, treatment modalities, and outcomes comparison between different WSES stages for ALCD
|
Total (n = 230)
|
0 (n = 70)
|
1A (n = 122)
|
1B (n = 16)
|
2A (n = 12)
|
2B (n = 6)
|
3 (n = 3)
|
4 (n = 1)
|
|
|---|---|---|---|---|---|---|---|---|
|
Abdominal pain, n (%)
|
230 (100%)
|
70 (100%)
|
122 (100%)
|
16 (100%)
|
12 (100%)
|
6 (100%)
|
3 (100%)
|
Yes
|
|
Days of abdominal pain, median (P25–P75)
|
2 (1–3)
|
2 (1–3)#
|
2 (1–3)§
|
4 (1–6.25)§
|
3 (2–7)*
|
1 (1–1.50)†,‡
|
2 (1–11.50)
|
3
|
|
Abdominal guarding, (%)
|
128 (55.65%)
|
35 (50%)§
|
65 (53.28%)
|
12 (75%)
|
6 (50%)§
|
6 (100%)*,#
|
3 (100%)
|
Yes
|
|
Fever > 38 °C, n (%)
|
49 (21.30%)
|
12 (17.14%)
|
27 (22.13%)
|
3 (18.75%)
|
5 (41.67%)
|
1 (16.67%)
|
2 (66.67%)
|
Yes
|
|
HR > 90 bpm, n (%)
|
39 (16.96%)
|
10 (14.29%)¶
|
21 (17.21%)
|
4 (25%)
|
1 (8.33%)
|
1 (16.67%)
|
1 (33.33%)*
|
Yes
|
|
WBC, median (P25–P75)
|
11.9 (9.55–14.5)
|
10.4 (8.3–13.7)†,‡,#,¶
|
12.2 (9.7–14.2)*,#,¶
|
13.9 (10.5–17.6)*
|
14.3 (12.9–17.8)*,†
|
13.1 (11.4–15.5)¶
|
17.9 (17.8–)*,†,§
|
12.6
|
|
Neutrophils (%), median (P25–P75)
|
75 (68.15–79.70)
|
72.25 (68.78–76.05)†,‡,#,§,¶
|
78.30 (74.83–80.80)*,§,¶
|
75.70 (63.73–87.28)*
|
79.40 (76.35–81.55)*,§,¶
|
86.95 (81.10–91.30)*,†,#
|
84.75 (82.6–)*,†,#
|
93.7
|
|
Lymphocytes (%), median (P25–P75)
|
15 (11.40–20.43)
|
17.35 (15.35–22.15)†,‡,#,§,¶
|
11.85 (9.33–15.25)*,§,¶
|
14.20 (11.90–21.35)*,§,¶
|
11.70 (8.05–14.60)*
|
8.30 (3.98–12.55)*,†,‡
|
8 (7.90–)*,†,‡
|
5.4
|
|
NLR, median (P25–P75)
|
5 (3.31–7.02)
|
4.16 (3.15–4.89)†,‡,#,§,¶
|
6.60 (5.06–8.36)*,§,¶
|
5.33 (2.63–6.39)*,§
|
6.63 (5.23–10.25)*
|
10.86 (6.65–23.44)*,†,‡
|
10.54 (10–)*,†
|
17
|
|
CRP, median (P25–P75)
|
68 (29–126)
|
45.50 (14–95.25)†,#,¶
|
70 (35.25–124.75)*,#,¶
|
72.50 (30.75–108.25)¶
|
149 (105–201)*,†,¶
|
93 (5–253.25)
|
252 (208–)*,†,‡,#
|
151
|
|
Fibrinogen, median (P25–P75)
|
632 (538.50–690.75)
|
551 (517.25–704.05)†,¶
|
673 (599–715.75)*,¶
|
635 (513–677)¶
|
659 (531.50–740.50)
|
631 (355.75–869.75)
|
867 (668–)*,†,‡
|
736
|
|
INR, median (P25–P75)
|
1.12 (1.07–1.21)
|
1.13 (1.09–1.18)#,¶
|
1.16 (1.08–1.28)#,¶
|
1.14 (1.05–1.22)#,¶
|
1.21 (1.15–1.29)*,†,‡
|
1.15 (1.04–1.24)
|
1.27 (1.26–)*,†,‡
|
1.32
|
|
Serum Albumin, median (P25–P75)
|
4.4 (4.1.–4.6)
|
4.2 (4–4.68)#
|
4.35 (4.10–4.50)#
|
4.35 (4.20–4.60)
|
3.9 (3.25–4.45)*,†
|
4 (3.78–4.65)
|
4.15 (4–)
|
3.7
|
|
Serum Creatinine, median (P25–P75)
|
0.84 (0.73–0.94)
|
0.80 (0.75–0.87)¶
|
0.87 (0.75–0.95)¶
|
0.78 (0.68–0.89)
|
0.70 (0.62–0.98)
|
0.90 (0.69–0.99)
|
1.28 (0.86–)*,†
|
0.88
|
|
Admission to hospital, n (%)
|
103 (44.78%)
|
17 (24.29%)†,‡,#,§,¶
|
50 (40.98%)*,‡,#,§
|
14 (87.50%)*,†
|
12 (100%)*,†
|
6 (100%)*,†
|
3 (100%)*
|
Yes
|
|
Length of stay (days), median (P25–P75)
|
5 (4–7.50)
|
5 (4–6.75)#,¶
|
5 (4–6)#,§,¶
|
5 (5–6)#
|
12 (6.50–22)*,†,‡
|
6.5 (5.75–15)†
|
9 (8–)*,†
|
9
|
|
Outpatient treatment, n (%)
|
127 (55.22%)
|
53 (75.71%)†,‡,#,§,¶
|
72 (59.02%)*,‡,#,§
|
2 (12.50%)*,†
|
0 (0%)*†
|
0 (0%)*,†
|
0 (0%)*
|
No
|
|
Readmission, n (%)
|
19 (8.26%)
|
3 (4.29%)
|
14 (11.48%)
|
2 (12.50%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
No
|
|
Previously admitted/outpatient
|
7/12
|
1/2
|
4/10
|
2/0
|
0/0
|
0/0
|
0/0
|
–/–
|
|
Percutaneous drainage, n (%)
|
8 (3.47%)
|
0 (0%)#
|
3 (2.46%)#
|
0 (0%)#
|
5 (41.67%)*,†,‡
|
0 (0%)
|
0 (0%)
|
No
|
|
Emergency surgery, n (%)
|
5 (2.17%)
|
0 (0%)#¶
|
1 (0.82%)#,¶
|
0 (0%)
|
2 (16.67%)*,†
|
0 (0%)
|
1 (33.33%)*,†
|
Yes
|
|
Asymptomatic 1-month, n (%)
|
189 (82.17%)
|
57 (81.42%)
|
104 (85.25%)#
|
13 (81.25%)
|
5 (41.66%)†
|
4 (66.66%)
|
3 (100%)
|
Yes
|
|
Recurrence 1-year, n (%)
|
57 (27.78%)
|
18 (25.71%)
|
28 (22.95%)
|
4 (25%)
|
5 (41.66%)
|
2 (33.33%)
|
0 (0%)
|
No
|
|
Lower GI endoscopy, n (%)
|
29 (12.61%)
|
26 (37.14)
|
43 (35.25%)
|
7 (43.75%)
|
2 (16.67%)
|
4 (66.67%)
|
1 (33.33%)
|
No
|
|
Neoplasm during follow-up, n (%)
|
1 (0.43%)
|
1 (1.43%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
No
|
|
Elective surgery, n (%)
|
12 (5.22%)
|
2 (2.86%)#
|
3 (2.70%)#
|
2 (12.50%)
|
5 (41.67%)*,†
|
0 (0%)
|
0 (0%)
|
No
|